In the Boardroom
Refine Search
Biotechnology
Aiming to expand its rare diseases gene therapy portfolio, USA-based Kriya Therapeutics revealed on Friday it has acquired Warden Bio, a company developing novel AAV-mediated gene therapies for glycogen storage disorders (GSDs). 8 January 2022
Biotechnology
Eikon Therapeutics, a pioneer in the application of live-cell super-resolution microscopy to drug discovery, has closed a $517.8 million Series B financing. 7 January 2022
Biotechnology
US precision cancer therapy specialist Blueprint Medicines has appointed Kate Haviland to succeed Jeff Albers as chief executive (CEO), effective April 4, 2022. 6 January 2022
Biosimilars
Effective January 3, German drugmaker STADA Arzneimittel is strengthening its biosimilars capabilities with the appointment of Erin Federman as global commercial head, Biosimilars and vice president. 5 January 2022
Biotechnology
Anders Ullman, currently a member of the board of directors at Swedish Orphan Biovitrum, also known as Sobi, will become head of R&D and chief medical officer and replace Dr Ravi Rao. 13 December 2021
Biotechnology
Swiss biotech ImmunOs Therapeutics today announced that Steve Coats has been appointed as chief development officer (CDO). 6 December 2021
Pharmaceutical
Privately-held Danish medical dermatology specialist LEO Pharma today said that its president and chief executive of two years, Catherine Mazzacco, has resigned from the position and will be leaving the company as of today. 30 November 2021
Biotechnology
French AI-driven drug combo specialist Pharnext has announced the appointment of Dr Burkhard Blank as chief medical officer (CMO) and Head of Research & Development effective January 1, 2022. 23 November 2021
Biotechnology
US biotech Biogen surprised industry watchers, with the announcement that Alfred (Al) Sandrock Jr, head of research and development, will retire from the company effective December 31, 2021. 17 November 2021
Pharmaceutical
The Sustainable Markets Initiative (SMI), a network of global CEOs and private sector corporations targeting planet-friendly growth, has created a new task force focused on the healthcare sector. 4 November 2021
Biotechnology
Swiss rare diseases specialist Santhera Pharmaceuticals today said it has appointed Stephanie Brown as president North America and a member of its executive management team, effective December 1. 4 November 2021
Biotechnology
Investors appeared unimpressed by changes to the leadership team at US oncology specialist Mirati Therapeutics, where former Ipsen boss David Meek took over as chief executive in September of this year. 2 November 2021
Biotechnology
Apart from financial results, clinical trial results were much in evidence among the news last week. Novartis’ already-marketed canakinumab missed Phase III clinical goals in lung cancer for a second time. Sanofi and Regeneron released new data on their Dupixent in the treatment of eosinophilic esophagitis along with plans for regulatory filings. Also, there was disappointment in the Alzheimer’s space, when US biotech Cortexyme last Tuesday reported missed endpoints in a Phase II/III of its candidate atuzaginstat. Meantime, the announcement that Alnylam’s long-time chief executive John Maragonore was leaving after 19 years came as a big surprise. 31 October 2021
Biotechnology
US a multi-asset longevity biotech Cambrian Biopharma today announced the closing of an oversubscribed Series C financing, which raised $100 million. 26 October 2021
Pharmaceutical
French drugmaker Ipsen has appointed Mari Scheiffele as executive vice president and president, Specialty Care International, effective November 1, 2021. 11 October 2021
Biotechnology
Ensoma, a Boston, USA-based gene therapy company advancing the future of medicine through precision in vivo engineering of blood and immune cells, today announced the appointment of Emile Nuwaysir as president, chief executive officer and member of the company’s board of directors. 11 October 2021
Pharmaceutical
Swiss privately-held ophthalmics company Oculis has appointed Dr Joanne Chang as chief medical officer and head of portfolio management. 7 October 2021
Biotechnology
Privately-held Danish vaccines company MinervaX has provided an update on clinical progress and announced changes to its executive and scientific advisory boards. 7 October 2021
Biotechnology
US clinical-stage biotech Pieris Pharmaceuticals (Nasdaq: PIRS) today announced the promotions of Thomas Bures to chief financial officer and Ahmed Mousa to chief business officer. 6 October 2021
Biotechnology
Roivant Sciences, a Switzerland-based a biopharma company, today announced that it has closed its business combination with Montes Archimedes Acquisition Corp, a special purpose acquisition company (SPAC), as well as a concurrent PIPE financing. 1 October 2021
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Biotechnology
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Biotechnology
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Biotechnology
US biotech major Biogen revealed it has appointed Daniel Quirk as chief medical officer and head of medical affairs. 29 October 2024
Pharmaceutical
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024
Biotechnology
AAVantgarde has announced the appointment of Lauren Kaskiel as chief business officer (CBO). 22 October 2024
Pharmaceutical
British artificial intelligence specialist BenevolentAI has announced the return of its founder, Ken Mulvany, as executive chairman. 18 October 2024
Biotechnology
Denmark’s Commit Biologics, a specialist in the activation of the complement system to treat cancer and autoimmune disease, has announced the appointment of Mikkel Wandahl Pedersen as chief scientific officer (CSO). 15 October 2024
Pharmaceutical
Canada-based biotech Sernova (TSX: SVA) has announced key new appointments to its executive leadership team. 15 October 2024
Biotechnology
French biotech Innate Pharma has appointed Jonathan Dickinson as its new chief executive (CEO) and chairman of the executive board, effective November 1, 2024. 14 October 2024
Biotechnology
Turnstone Biologics has announced a major restructuring of its operations, cutting its workforce by approximately 60%. 14 October 2024
Pharmaceutical
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
Biotechnology
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Biotechnology
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
Biotechnology
French cancer vaccine focused biotech Oncovita has appointed Dr Stéphane Altaba as its new chief executive (CEO). 9 October 2024
Biotechnology
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024
Biotechnology
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
Pharmaceutical
US pharma giant Pfizer (NYSE: PFE) has announced that John McGinley has been appointed UK managing director and country president. 7 October 2024
Pharmaceutical
ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announces the appointment of Nicholas Ostrout, as vice president of corporate development and strategy. 7 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze